Literature DB >> 28946800

The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia.

Tanja Novakovic1, Antony P Martin2, Mark Parker3, Alessandra Ferrario4, Simo Vukovic5, Krzysztof Łanda6, Jaroslav Duba7, Dávid Dankó8, Nikolaos Kotsopoulos9,10, Brian Godman2,11,12, Jelena Ristic1, Danka Stefanovic1, Danka Tesic1.   

Abstract

The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia organised a one day international conference on the value of innovation in decision-making in health care in Central and Eastern Europe. The focus of the conference was on reimbursement decisions for medicines using health technology assessment and the use of managed entry agreements (MEAs). The objectives of this conference were firstly to discuss the challenges and opportunities with the use of MEAs in Central and Eastern European countries; secondly the role of patient registries especially with outcome based schemes, and finally new approaches to improve accessibility to new medicines including better managing their entry.

Entities:  

Keywords:  Central and Eastern Europe; Serbia; health technology assessment; innovation; managed entry agreements

Mesh:

Year:  2017        PMID: 28946800     DOI: 10.1080/14737167.2017.1385394

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  1 in total

1.  Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in 'Rich' Countries?

Authors:  Alan Haycox
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.